Von Willebrand Disease Type 2A: An Update.
This review offers an updated synthesis of Type 2A von Willebrand Disease, focusing on its pathophysiology and management but lacks new experimental insights.
Where it sits
this study against the rest of the desmopressin corpusSummary and findings
The paper reviews von Willebrand Disease Type 2A, focusing on its pathophysiology, clinical manifestations, and management strategies, including the use of desmopressin. It highlights the impaired VWF-dependent platelet adhesion due to reduced high- and intermediate-molecular-weight multimers. The review discusses diagnostic approaches and therapeutic strategies based on bleeding severity.
Abstract
<h4>Abstract</h4>Dysfunctional or quantitatively deficient von Willebrand factor (VWF) underlies von Willebrand disease (VWD), the most common inherited bleeding disorder. Type 2A VWD is a qualitative defect marked by impaired VWF-dependent platelet adhesion, typically reflected in disproportionately reduced ratios of platelet-dependent VWF activity to antigen (VWF activity/VWF:Ag) and collagen binding to antigen (VWF:CB/VWF:Ag). This phenotype results from a selective reduction or lack of high- and intermediate-molecular-weight multimers, which are essential for effective hemostasis under high shear stress. The lack of multimer arises from impaired multimer assembly and/or increased proteolytic cleavage of VWF by ADAMTS13. Clinically, type 2A tends to present with greater severity than other type 2 variants, manifesting as mucocutaneous bleeding, often including heavy menstrual bleeding, epistaxis, post-surgical bleeding and gastrointestinal hemorrhage from angiodysplasia. Diagnosis relies on functional assays and VWF multimer analysis, supported by genetic testing that identifies subtype-specific mutations affecting VWF multimeric structure and therefore its function. Type 2A is typically inherited in an autosomal dominant manner, with rare exceptions of autosomal recessive inheritance. Structural and molecular studies are continuing to elucidate how domain-specific variants disrupt multimeric structure and thus interactions with its ligands. Management is guided by bleeding severity and includes desmopressin (following responsiveness testing) and VWF replacement therapy. This review provides an in-depth update on type 2A VWD, covering its epidemiology, pathophysiology across distinct subtypes, clinical manifestations, diagnostic approach, molecular and structural insights, and current therapeutic strategies.
Background
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, with Type 2A characterized by a qualitative defect in von Willebrand factor (VWF). This defect leads to impaired platelet adhesion due to a reduction in high- and intermediate-molecular-weight multimers. Understanding the pathophysiology and management of Type 2A VWD is crucial for improving patient outcomes.
Methods
This paper is a review article, summarizing existing literature on Type 2A VWD. It covers the epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and therapeutic strategies. The review does not involve new experimental data or clinical trials.
Results
Not reported in abstract.
Interpretation
The review provides a comprehensive update on Type 2A VWD, emphasizing the importance of understanding the molecular and structural basis of the disease. While it outlines current management strategies, including desmopressin and VWF replacement therapy, the clinical significance of these treatments is not evaluated with new data. The review serves as a valuable resource for clinicians and researchers but does not advance new hypotheses or findings.
Key findings
- Type 2A VWD involves impaired VWF-dependent platelet adhesion.
- Disproportionately reduced VWF activity/VWF:Ag and VWF:CB/VWF:Ag ratios.
- Selective reduction or lack of high- and intermediate-molecular-weight multimers.
- Type 2A VWD presents with mucocutaneous bleeding and other severe symptoms.
- Diagnosis relies on functional assays and VWF multimer analysis.
Limitations
- No new experimental data presented
- Review format limits novel insights
- Potential for outdated information
- No quantitative findings reported